

Dissecting the Decision:

Documenting and Discussing the Clinical Practice Patterns of Hematologic Oncology Investigators in the Management of Mantle Cell Lymphoma

CME Information

TARGET AUDIENCE

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of mantle cell lymphoma (MCL).

OVERVIEW OF ACTIVITY

While MCL represents only approximately 6% of all non-Hodgkin lymphoma cases, it remains one of the 4 most frequently diagnosed subtypes and is widely viewed as harboring the worst disease characteristics and exhibiting the most destructive growth pattern. The vast majority of patients will need active treatment at some point, and it has long been established that fit individuals should receive high-dose chemoimmunotherapy followed by autologous stem cell transplant, with chemoimmunotherapy alone being employed for the elderly or those unable to tolerate more intensive approaches. Despite broad agreement among MCL investigators regarding this risk- and age-stratified algorithm, lingering debate still exists about the contribution of and indications for maintenance therapy in these individuals. Similarly, the treatment of first and subsequent relapses is significantly less well defined, and it is in this setting that treatment options have recently expanded, with many newer agents demonstrating significant activity against MCL. While the availability of multiple therapeutic options is welcomed by patients and clinicians alike, it may also challenge clinical decision-making. As such, a great need exists for resources that deliver expert perspectives and dedicated discussion of the relative benefits and risks of each available treatment as well as those with promising early-phase clinical trial data.

These proceedings from a CME/CNE symposium held during the 2018 Pan Pacific Lymphoma Conference use an innovative strategy to formally document and present the perspectives, experiences and preferred treatment approaches of 25 lymphoma-specific investigators. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of MCL with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

- Individualize the selection of systemic therapy for patients with newly diagnosed MCL, considering the patient's clinical presentation, fitness and willingness to undergo

autologous stem cell transplant and psychosocial status (eg, desire for active treatment).

- Formulate an evidence-based approach to the use of maintenance therapy for transplant-eligible and transplant-ineligible patients with MCL.
- Recall the mechanisms of action, efficacy and safety of approved agents commonly employed for the treatment of relapsed/refractory (R/R) MCL to determine the current and/or potential utility of each in clinical practice.
- Appreciate the recent FDA approval of the second-generation BTK inhibitor acalabrutinib for patients with R/R MCL, and discern how this agent can be appropriately and safely integrated into routine clinical practice.
- Design a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies in the management of MCL to support quality of life and continuation of therapy.
- Recall available and emerging data with other investigational agents currently under evaluation for MCL, and where applicable, refer eligible patients for trial participation.

CME/CNE ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education (UNMC CCE), University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) and Research To Practice.

PHYSICIANS: The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with

distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is provided for 2.25 contact hours under ANCC criteria.

FOR SUCCESSFUL COMPLETION

CME: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at: ResearchToPractice.com/Lymphomas18/MCL/CME.

CNE: This CNE activity consists of a video component. To receive credit, the participant should review the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at: ResearchToPractice.com/Lymphomas18/MCL/CNE.

CONTENT VALIDATION AND DISCLOSURES

It is the policy of the UNMC CCE and UNMC CON CNE to ensure balance, independence, objectivity and scientific rigor in all their educational symposia. All faculty, planners and managers participating in these activities are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME/CNE about the products or services of the commercial interest. UNMC CCE, UNMC CON CNE and Research To Practice ensured that any conflicts of interest were resolved before the educational activity occurred.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Jeremy Abramson, MD

Director of the Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Humanigen Inc, Juno Therapeutics, Karyopharm Therapeutics, Merck, Novartis, Seattle Genetics, Verastem Inc.

Brad S Kahl, MD

Professor of Medicine
Washington University School of Medicine
St Louis, Missouri

Consulting Agreements: Celgene Corporation, Genentech, Pharmacyclics LLC, an AbbVie Company.

John P Leonard, MD

Richard T Silver Distinguished Professor of Hematology and Medical Oncology

Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Consulting Agreements: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biotest Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Gilead Sciences Inc, Juno Therapeutics, Karyopharm Therapeutics, MEI Pharma, Novartis, Pfizer Inc, Sutro Biopharma Inc, United Therapeutics Corporation.

Julie M Vose, MD, MBA

Neumann M and Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska

Consulting Agreements: AbbVie Inc, Epizyme Inc, Karyopharm Therapeutics, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche Laboratories Inc, Sandoz, Vaniam Group; **Contracted Research:** Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Incyte Corporation, Kite Pharma Inc, Merck, Novartis, Seattle Genetics.

MODERATOR — **Dr Love** is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Bodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE CME/CNE PLANNING

COMMITTEE MEMBERS, STAFF AND REVIEWERS —

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and the UNMC CCE do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: August 2018

Expiration date: August 2019

Select Publications

Julie M Vose, MD, MBA

Dreyling M et al. **Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** *Ann Oncol* 2017;28(Suppl 4):62-71.

Fernandez V et al. **Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.** *Cancer Res* 2010;70(4):1408-18.

Ferrando AA. **SOX11 is a mantle cell lymphoma oncogene.** *Blood* 2013;121(12):2169-70.

Fisher RI et al. **Diffuse aggressive lymphoma.** *Hematology Am Soc Hematol Educ Program* 2004;221-36.

Hoster E et al. **Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the European Mantle Cell Lymphoma Network.** *J Clin Oncol* 2016;34(12):1386-94.

Hoster E et al. **Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.** *J Clin Oncol* 2014;32(13):1338-46.

Hoster E et al. **A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.** *Blood* 2008;111(2):558-65.

Le Gouill S et al. **Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma.** *N Engl J Med* 2017;377(13):1250-60.

Lichtman MA et al. **Williams Hematology.** 7th ed. New York, NY: McGraw Hill; 2006.

Martin P et al. **Outcome of deferred initial therapy in mantle-cell lymphoma.** *J Clin Oncol* 2009;27(8):1209-13.

Rummel MJ et al. **Two years rituximab maintenance vs observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).** *Proc ASCO* 2016;Abstract 7503.

Rummel MJ et al. **Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial.** *Lancet* 2013;381(9873):1203-10.

Seto M. **Cyclin D1-negative mantle cell lymphoma.** *Blood* 2013;12(8):1249-50.

Vegliante MC et al. **SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.** *Blood* 2013;121(12):2175-85.

Wang ML et al. **Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.** *N Engl J Med* 2013;369(6):507-16.

John P Leonard, MD

Baiocchi RA et al. **Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.** *Cancer* 2011;117(11):2442-51.

Dietrich S et al. **Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).** *Ann Oncol* 2014;25(5):1053-8.

Eskelund CW et al. **TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.** *Blood* 2017;130(17):1903-10.

Fenske TS et al. **Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality.** *J Clin Oncol* 2014;32(4):273-81.

Friedberg JW et al. **The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.** *Blood* 2011;117(10):2807-12.

Furtado M et al. **Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.** *Br J Haematol* 2015;168(1):55-62.

García-Noblejas A et al. **Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: A retrospective study of the Spanish experience.** *Ann Hematol* 2014;93(9):1551-8.

Goy A et al. **Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study.** *J Clin Oncol* 2013;31(29):3688-95.

Select Publications

Goy A et al. **Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study.** *Ann Oncol* 2008;20(3):520-5.

Jerkeman M et al. **Ibrutinib-lenalidomide-rituximab in patients with relapsed/refractory mantle cell lymphoma: First results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial.** *Proc ASH* 2016;Abstract 148.

Lee HJ et al. **Phase II study of bortezomib in combination with cyclophosphamide and rituximab for relapsed or refractory mantle cell lymphoma.** *Oncologist* 2017;22(5):549-53.

Martin P et al. **Postibrutinib outcomes in patients with mantle cell lymphoma.** *Blood* 2016;127(12):1559-63.

Rule S et al. **Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies.** *Proc EHA* 2016;Abstract S438.

Wang ML et al. **Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.** *N Engl J Med* 2013; 369(6):507-16.

Wang M. **Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial.** *Lancet Oncol* 2012;13:716-23.

Brad S Kahl, MD

Barf T et al. **Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile.** *J Pharmacol Exp Ther* 2017;363(2):240-52.

Cheson BD et al. **Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification.** *J Clin Oncol* 2014;32(27):3059-68.

Wang M et al. **Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicenter, phase 2 trial.** *Lancet* 2018;391(10121):659-67.

Wang M et al. **Efficacy and safety of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma in the phase 2 ACE-LY-004 study.** *Blood* 2017;130(Suppl 1):155.

Jeremy Abramson, MD

Abramson JS et al. **Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.** *Proc ASCO* 2018;Abstract 7505.

Bentz M et al. **t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia.** *Genes Chromosomes Cancer* 2000;27(3):285-94.

Cunningham D et al. **Results of the mantle cell lymphoma subset from a phase 2a study of copanlisib, a novel PI3K inhibitor, in patients with indolent and aggressive lymphoma.** *Blood* 2015;126(23):3935.

Davids MS et al. **Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma.** *J Clin Oncol* 2017;35(8):826-33.

Dreyling M et al. **Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.** *Ann Oncol* 2017;28(9):2169-78.

Eyre T et al. **Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibition therapy.** *Proc EHA* 2018;Abstract S855.

Gopal AK et al. **PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma.** *N Engl J Med* 2014; 370(11):1008-18.

Leonard JP et al. **Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.** *Blood* 2012;119(20):4597-607.

Li Y et al. **FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.** *Oncogene* 2016;35(48):6223-34.

Morschhauser F et al. **Clinical activity of abemaciclib (LY2835219), a cell cycle inhibitor selective for CDK4 and CDK6, in patients with relapsed or refractory mantle cell lymphoma.** *Blood* 2014;124(21):3067.

Portell CA et al. **Initial report of a multi-institutional phase I/Ib study of ibrutinib with venetoclax in relapsed or refractory mantle cell lymphoma.** *Blood* 2016;128(22):2958.

Select Publications

Tam CS et al. **Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma.** *N Engl J Med* 2018;378(13):1211-23.

Turtle CJ et al. **Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.** *Sci Transl Med* 2016;8(355):355ra116.